Search Results for: MANAGEMENT INSIGHT Pharmaceutical Innovation in
Articles
QUALITY-BY-DESIGN - Quality-by-Design: The Good, The Bad, The Inevitable October 2, 2014
Michael Lowenborg believes in essence, QbD can be interpreted as a way to maximize time and cost savings by better understanding the components and processes necessary to optimize a drug product’s safety, efficacy, and quality at every stage in development.
BIOAVAILABIITY ENHANCEMENT - Innovators & Corporate Cultures: Symbiotic Relationships July 8, 2014
Marshall Crew, PhD, explores some of the key features of people and organizations that lead to the innovations and products, and hopes that by example, insights can be acquired that will be useful in his colleagues respective organizations and that might ultimately lead to more innovation in the industry.
IDENTITY HUB - Leveraging Identity Hubs to Speed the Drug Development & Delivery Process & Maximize Revenue Opportunities July 7, 2014
Vijay Takanti, MS, MBA, believes the Exostar Life Sciences Identity Hub is a proven implementation of the identity hub concept that provides the trust necessary for enterprises and individuals to collaborate with confidence.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing - Product Differentiation Is Critical May 8, 2014
Contributor Cindy H. Dubin speaks with several of these suppliers and manufacturers about the importance of customization and differentiation as the key to pharma companies staying competitive in the prefilled syringe space.
FIXED-DOSE COMBINATIONS - Fixed-Dose Combination Products – A Review (Part 2 – Analysis) April 1, 2014
Tugrul T. Kararli, PhD, MBA, Kurt Sedo, and Josef Bossart, PhD, believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and in a series of three articles, examine the past, present, and future of these products with the intent of understanding their whats and whys.
Cardiovascular Disease Market: US to Lead Modest Growth; Electronic Cigarettes Could Be the Next Blockbuster December 11, 2013
The global market for Cardiovascular Disease (CVD) - composed of Heart Failure (HF), Myocardial Infarction (MI), and Acute Coronary Syndrome...MARKET BRIEF - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs November 18, 2013
Adam M. Dion, MS, summarizes GlobalData’s recent CRO Benchmark Report and believes the dynamics of pharmaceutical outsourcing and location decisions in emerging markets are changing. Cost reduction is being augmented and will gradually be eclipsed by footprint growth as a major factor shaping decisions, and CROs are realizing that the ability to be on the ground closer to their customers is a key building block to establishing sustainable, long-term relationships with clients.
FORMULATION DEVELOPMENT - Trends & Opportunities in Particle Design Technologies - Life Sciences & Biopharma in the Spotlight April 30, 2013
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical industry.
MARKET FORECASTING - Monte Carlo-Based Forecasting: How to Deal With Uncertainty April 30, 2013
Jemma Lampkin and Gerard Loosschilder, PhD, show how Monte Carlo-based forecasts are better at handling uncertainties, turning them into valuable tools for product managers and marketers engaged in strategic business planning.
2/20/2013 February 17, 2013
Argos Therapeutics Announces Updated Phase II Data Argos Therapeutics Inc. recently announced updated results from its Phase II study of...2/6/2013 January 31, 2013
Foresite Capital Closes $100 Million Fund for Late-Stage Biotechs Biotech venture capital isn't what it used to be, but there's...12/27/2012 December 20, 2012
Radius & 3M Announce Exclusive Agreement Radius Health, Inc. and 3M Drug Delivery Systems recently announced an exclusive partnership agreement...12/12/2012 December 10, 2012
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs The challenges inherent in the pharmacological management of rheumatic diseases...10/24/2012 October 21, 2012
Avantor & Rubicon to Collaborate on Next-Generation Functional Excipients Avantor Performance Materials recently announced it has signed a collaboration...10/16/2012 October 11, 2012
Catalent Licenses Innovative Technology Following a successful research collaboration, Catalent Pharma Solutions recently announced it has taken an exclusive license...11/01/2011 October 27, 2011
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing...8/9/2011 August 4, 2011
Celgene & Acceleron Enter Agreement Worth Up to $242 Million Celgene Corporation and Acceleron Pharma, Inc. recently announced they...
